CD73+ Mesenchymal Stem Cells Ameliorate Myocardial Infarction by Promoting Angiogenesis
| Autor: | Hongbo Zuo, Qiong Li, Huifang Hou, Min Zhang, Xia Yu, Meng Li, Jianhui Gao, Zhikun Guo, Zongjin Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
QH301-705.5
Angiogenesis Cell Adipose tissue Flow cytometry Cell and Developmental Biology angiogenesis Paracrine signalling medicine Myocardial infarction Biology (General) Original Research medicine.diagnostic_test adipose derived mesenchymal stem cells business.industry Mesenchymal stem cell Cell Biology medicine.disease VEGF Transplantation myocardial infarction medicine.anatomical_structure CD73 Cancer research business Developmental Biology |
| Zdroj: | Frontiers in Cell and Developmental Biology Frontiers in Cell and Developmental Biology, Vol 9 (2021) |
| ISSN: | 2296-634X |
| DOI: | 10.3389/fcell.2021.637239 |
| Popis: | With multipotent differentiation potential and paracrine capacity, mesenchymal stem cells (MSCs) have been widely applied in clinical practice for the treatment of ischemic heart disease. MSCs are a heterogeneous population and the specific population of MSCs may exhibit a selective ability for tissue repair. The aim of our research was to adapt the CD73+ subgroup of adipose derived MSCs (AD-MSCs) for the therapy of myocardial infarction (MI). In this research, AD-MSCs were isolated from adipose tissue surrounding the groin of mice and CD73+ AD-MSCs were sorted using flow cytometry. To investigate the therapeutic effects of CD73+ AD-MSCs, 1.2 × 106 CD73+ AD-MSCs were transplanted into rat model of MI, and CD73– AD-MSCs, normal AD-MSCs transplantation served as control. Our results revealed that CD73+ AD-MSCs played a more effective role in the acceleration function of cardiac recovery by promoting angiogenesis in a rat model of MI compared with mixed AD-MSCs and CD73– AD-MSCs. Moreover, with the expression of CD73 in AD-MSCs, the secretion of VEGF, SDF-1α, and HGF factors could be promoted. It also shows differences between CD73+ and CD73– AD-MSCs when the transcription profiles of these two subgroups were compared, especially in VEGF pathway. These findings raise an attractive outlook on CD73+ AD-MSCs as a dominant subgroup for treating MI-induced myocardial injury. CD73, a surface marker, can be used as a MSCs cell quality control for the recovery of MI by accelerating angiogenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|